SYSTOPIC

What SYSTOPIC does

Systopic Laboratories Private Limited is an Indian pharmaceutical manufacturer headquartered in New Delhi that has operated since 1984, producing and marketing branded generic formulations across nine therapeutic segments: Dermatology, Orthopaedics, Gynaecology, Diabetology, Cardiology, Gastroenterology, Anti Allergics, Surgery, and ENT. The portfolio spans small-molecule generics and proprietary delivery formats, including claimed first-to-market innovations such as the world's first three strengths of Diclofenac SR (75/100/150 mg), India's first 4% Diclofenac Gel with Nano Technology, ETOS-P (bilayered technology with BCD advantage), and the first Indian Amlodipine brand (Amcard, 1994). Key brands include NEWTEL, Orvas, Amcard, Normaxin, Cyra, ETOS, NAC, Sysfol, Levosiz, AIR, the AF antifungal range, and Itrasys.

The company sells exclusively to the Indian healthcare market via a direct field-sales model: a dedicated sales force of 1,150+ professionals promotes products to 91,000+ members of the Indian medical community. Go-to-market activity combines medical-conference participation (IADVL, Indian Orthopaedic Association, RSSDI, CSI, ISG, AICOG, AOI, API), corporate training, and digital presence (LinkedIn, Facebook, product launch videos). Supporting infrastructure includes a corporate training academy at IMT Manesar, Gurgaon, a pharmacovigilance/regulatory function, and ongoing product launches (e.g., ISRYL TRIO 1 and 2 in Diabetology). Ownership is private and described as promoter-led under Managing Director P.K. Dutta, with no disclosed external investors.

Name

SYSTOPIC

Legal name

Systopic Laboratories Private Limited

Website

https://systopic.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Systopic Laboratories Private Limited is an Indian pharmaceutical manufacturer founded in 1984 that produces and sells branded generic formulations across nine therapeutic segments, reaching 91,000+ doctors through a direct 1,150+ person field-sales force.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Pharmaceutical manufacturing
• Branded generic drugs
• Dermatology formulations
• Orthopaedic medications
• Cardiology products

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Systopic generates revenue through the manufacturing and sale of pharmaceutical formulations across multiple therapeutic segments including dermatology, orthopaedics, gynaecology, diabetology, cardiology, gastroenterology, anti allergics, surgery, and ENT. Products are promoted directly to healthcare providers through their sales force of over 1150 professionals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Systopic Laboratories Private Limited manufactures and sells branded pharmaceutical formulations across nine therapeutic segments including dermatology, orthopaedics, gynaecology, diabetology, cardiology, gastroenterology, anti-allergics, surgery, and ENT. Products are promoted through a direct field sales force of over 1,150 professionals to more than 91,000 members of the Indian medical community.

Product overview

Systopic Laboratories Private Limited is an Indian pharmaceutical company established in 1984, offering a diverse portfolio of quality innovative pharmaceutical products across multiple therapeutic segments. The company operates as a multi-segment pharmaceutical portfolio with distinct product lines in Dermatology (antifungals, corticosteroids, anti-acne), Orthopaedics (NSAIDs, pain relievers, supplements), Gynaecology (pregnancy support, DUB management, anti-infectives), Diabetology (Sulfonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, combinations), Cardiology (ARBs, statins, calcium channel blockers, beta blockers), Gastroenterology (PPIs, IBS management, hepatoprotectives, probiotics), Anti Allergics (antihistamines, INCS nasal sprays), Surgery (PPI range, NSAIDs, pre/post-surgical care), and ENT. Key brands include NEWTEL, ORVAS, AMCARD, Normaxin, Cyra, ETOS, NAC, SYSFOL, Levosiz, AIR, AF Range, and Itrasys. The company markets through a high-performance sales force of over 1150 professionals promoting products to over 91,000 members of the Indian medical community.

Differentiator

Problem solved

Functional benefit

Products and services

• Normaxin (IBS management) Flagship gastroenterology brand offering a triple combination (antispasmodic + anti-secretory + anxiolytic) for Irritable Bowel Syndrome management in the Indian market.
• Amcard (Amlodipine) Calcium-channel blocker (Amlodipine) — the first Indian Amlodipine brand — for hypertension and related cardiovascular conditions.
• NAC SR (Diclofenac sustained release) Diclofenac sustained-release pain management range for orthopaedics and surgery; Systopic was the world's first company to offer three strengths (75/100/150 mg) of Diclofenac SR.
• ETOSYS (Haemostatic therapy) Haemostatic agent for gynaecology and surgical use, redefining haemostatic therapy in India.
• Topisal 6% (Scaly dermatoses) Topical corticosteroid for scaly dermatoses in dermatology, available in lotion and ointment formulations including combination variants.
• Piosys (Pharmacoeconomics / Diabetology) Pioneering pharmacoeconomics initiative in the diabetology segment, addressing cost-effective diabetes management.
• AF-400 (Antifungal) Antifungal formulation representing a pathbreaking advance in antifungal therapy for dermatological fungal infections.
• Salcare (Skin care) Dermatology skin care range redefining skin care for Indian patients.
• AF-300 (Fluconazole) Trendsetting Fluconazole-based antifungal therapy for dermatology fungal infections.
• VOGS (Voglibose) Alpha-glucosidase inhibitor (Voglibose) for postprandial glucose control in diabetology.
• Systaflam Spray / Systaflam-MR Diclofenac topical gel and spray range — India's first Diclofenac spray with Mephenesin as muscle relaxant — for orthopaedic pain management.
• TOPP / Topmost Pantoprazole Pantoprazole-based proton pump inhibitor for acid-peptic disorders in gastroenterology.
• Kinetozyme (Inflammation / Oedema) Enzyme-based anti-inflammatory formulation for inflammation and oedema in orthopaedic conditions.
• Sysfol Activ (Active Folic Acid) Active folic acid supplement for gynaecology and pregnancy support within the Sysfol exclusive folic acid brand portfolio.
• ETOS-P (Bilayered Diclofenac + Paracetamol) Orthopaedic pain product using proprietary bilayered technology with BCD advantage — the only brand in India with this technology in the orthopaedic segment.
• NEWTEL (Telmisartan ARB range) Telmisartan-based Angiotensin II Receptor Blocker range for hypertension and cardiovascular conditions, with multiple combination variants.
• ORVAS (Atorvastatin) Atorvastatin statin brand for lipid management in cardiology; positioned as a market leader in the Indian Atorvastatin segment.
• Cyra (Rabeprazole PPI) Rabeprazole-based proton pump inhibitor for acid-peptic disorders, with multiple combination variants for gastroenterology and surgery.
• ISRYL (Glimepiride) Glimepiride sulfonylurea range for type-2 diabetes, with multiple strengths and Metformin combinations including ISRYL TRIO for comprehensive glycaemic control.
• Levosiz / AIR / AIR FZ (Anti-allergy range) Comprehensive anti-allergy portfolio spanning oral antihistamines (Levocetirizine, Fexofenadine), combination therapies with Montelukast, and intranasal corticosteroid nasal sprays for allergic rhinitis.
• SYSFOL (Folic acid range) Exclusive folic acid brand for pregnancy and gynaecology with multiple variants tailored to maternal-health needs.
• NIDAGEN (Progesterone) Progesterone-based pregnancy support product for gynaecology, available in multiple strengths including sustained-release formulations.
• Analiv (Hepatoprotective) Natural hepatoprotective (liver activator) available in oral and injectable forms for gastroenterology.
• Amrosys (Multifaceted Antifungal) Multifaceted antifungal cream for dermatology, part of Systopic's House of Antifungals range combining multiple antifungal mechanisms.
• DAPAGAIN (Dapagliflozin) SGLT-2 inhibitor (Dapagliflozin) for type-2 diabetes management within Systopic's diabetology portfolio.
• Itrasys (Itraconazole) Itraconazole-based antifungal range spanning dermatology and ENT indications, including combination variants.

Quantifiable outcome

• Serving medical fraternity for over 40 years
• +4 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered minor.

• CODFI (Contact and Occupational Dermatoses Forum of India)minorOthersProfessional association supporting dermatology standards. Systopic participates in CODFI activities to ensure constant diligence in meeting industry standards.
• Nail Society of IndiaminorOthersProfessional dermatology association. Systopic has associations with this body to ensure constant diligence in meeting industry standards.
• Indian Orthopaedic AssociationminorOthersNational orthopaedic association. Systopic participated in IOACON-2019 conference at Biswa Bangla Convention Centre, Kolkata.
• Research Society for the Study of Diabetes in India (RSSDI)minorOthersDiabetes research society. Systopic participated in RSSDI 2019 conference at JECC, Jaipur.
• Cardiological Society of India (CSI)minorOthersNational cardiology association. Systopic participated in CSI 2019 conference in Delhi.
• Indian Society of GastroenterologyminorOthersNational gastroenterology society. Systopic participated in ISGCON-2019 in Kolkata.
• All India Congress of Obstetrics & Gynaecology (AICOG)minorOthersNational OB-GYN congress. Systopic participated in AICOG-2020-21 in Indore.
• Indian Association of Dermatologists, Venereologists & Leprologists (IADVL)minorOthersNational dermatology association. Systopic participated in DERMACON-2020-21 at Hitex Exhibition Center, Hyderabad.
• The Association of Physicians of IndiaminorOthersNational physicians association. Systopic participated in APICON-2020-21 in Jaipur.
• Asia-Oceania ORL-HNS Congress & Association of Otolaryngologists of IndiaminorOthersCombined ENT congress. Systopic participated in 15th Asia-Oceania ORL-HNS Congress 2020 at Chitnavis Centre, Nagpur.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Intas Pharmaceuticals: Privately held Indian pharma with multi-therapeutic portfolio across chronic and specialty care, operating via a similar field-sales-driven model in the Indian domestic market.
• Torrent Pharmaceuticals: Mid-sized Indian branded generics company with strong chronic-care and dermatology presence; comparable therapeutic footprint (cardiology, diabetology, gastro, dermatology) and physician-channel orientation.
• Alkem Laboratories: India-focused branded pharma operating across anti-infectives, gastro, pain, and chronic care; comparable multi-segment breadth and similar distribution-led go-to-market model.
• Glenmark Pharmaceuticals: Indian-headquartered branded pharma with overlapping therapeutic categories (dermatology, cardiology, diabetology, respiratory) and similar chronic-care brand-driven strategy.
• Mankind Pharma: Large Indian branded pharma with multi-therapeutic portfolio (cardio, anti-infectives, gastro, dermatology) and an India-focused field-sales model of comparable scale; the closest structural analog to Systopic's 1,150-rep detailing 91,000+ doctors approach.

Broad incumbents

• Cipla: Major Indian pharma with broad respiratory, cardiac, anti-infective, and chronic-care portfolio; competes head-on with Systopic in cardiology, gastro, and anti-allergics but at a far larger scale.
• Dr. Reddy's Laboratories: Leading Indian pharma with branded generics across dermatology, gastro, cardiology, and pain; meaningful overlap with Systopic's portfolio but with global reach and proprietary pipeline.
• Sun Pharmaceutical Industries: Largest Indian pharma by revenue with deep presence across all of Systopic's therapeutic segments (dermatology, orthopaedics, cardiology, diabetology, gastro); dominant benchmark but vastly larger and globally diversified.
• Lupin Limited: Indian major with branded presence in cardiology, diabetology, gastro, and dermatology; comparable therapeutic overlap and physician-channel strategy at significantly larger scale.

Emerging players

• Emami (Emami Pharma/Zandu): Indian pharma and consumer health player with healthcare portfolio spanning dermatology, pain, and chronic care; comparable in therapeutic overlap though less focused on ethical/prescription detailing.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/systopiclab
• LinkedInlinkedin.com/company/systopic

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SYSTOPIC